Maurice Ferre, M.D.
CEO & Chairman @ InSightec
Miami, United States
Maurice Ferre, M.D. is a Series A investor at InSightec in Miami focused on Medical Device and Medical. Dr. Maurice R. Ferré was the founding President and Chief Executive Officer of MAKO Surgical Corp, serving from 2004 until the acquisition of the company by Stryker Corp. for $1.7 billion in 2014.In June 2007, Dr. Ferré received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. In 1993, he foundedVisualization Technology, Inc., a medical device company for image-guided surgery, where he served as Chief Executive Officer until 2002 when the company was acquired by GE Healthcare, the healthcare division of the General Electric Company. Dr. Ferré served as Vice President of Strategic Development for GE Navigation, a Division of GE Healthcare, until 2004.Dr. Ferré holds an M.D. and a Master’s degree in Public Health from Boston University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Maurice Ferre, M.D. invests in
Stages Maurice Ferre, M.D. invests in
Countries Maurice Ferre, M.D. invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $10M–$30M
Investment Focus
Industry
- Medical Device 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Big Data 1 (17%)
- Hardware 1 (17%)
Stage
- Series A 2 (33%)
- Seed 1 (17%)
- Angel 1 (17%)
- Series B 1 (17%)
Country
- United States 3 (50%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DermaSensor
|
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $10M / Series B / Jun 15, 2022 | |
|
DermaSensor
|
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $10M / Series A / Jun 15, 2022 | |
TympaHealth
|
TympaHealth has developed the world's first ear and hearing health assessment system. The Tympa system empowers non-specialists to perform high definition digital otoscopy, microsuction wax removal and a hearing screening, all in a single 30 minute appointment. Users can also upload patient images and video to the secure cloud, where they canbe reviewed by ENT specialists anywhere in the world. | $8M / Seed / Feb 17, 2022 | |
Heru
|
Heru Inc. (www.SeeHeru.com) has developed patented autonomous AI-powered vision diagnostics and augmentation software for use on commercially available AR/VR devices. This technology exceeds traditional standards of care in clinical equivalence, usability, cost, size, and portability. Heru is the only cross-platform solution that canautonomously diagnose vision defects and customize individual vision augmentation based on the user’s unique vision defects. Heru originated as a spinout from Bascom Palmer Eye Institute. In December 2020, Heru announced FDA registration and a seed round led by Fred Drasner, Maurice R. Ferre, M.D., Fred H. Moll, M.D., and a consortium of investors with extensive experience developing, launching, and scaling cutting-edge medical technologies. | $30M / Series A / May 20, 2021 | |
|
DermaSensor
|
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $11.5M / Series A / Jun 04, 2020 | |
Naya Health
|
Naya Health reinvents nutrition for both babies and families with ingenious products and game-changing insights.Naya Health Co., is a seed stage company developing digital, consumer-focused health products that will revolutionize the well-being and lifestyle of mothers and babies. The company's initial product is a first-of- kind, radicallyimproved breast pump for nursing moms. Naya Health helps modern mothers reach their breastfeeding goals by offering products that integrate into a mom’s busy life. | $700K / Angel / Nov 27, 2014 |
Co-Investors
About InSightec
InSightec is the pioneer and global leader in MR guided focused ultrasound technology for image guided acoustic surgery.ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology. The ExAblate system received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment ofsymptomatic uterine fibroids. ExAblate received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world.
InSightec Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Maurice Ferre, M.D.
CEO & Chairman
|
|||
Alexandru Popescu
Commercial Leader EEMEA& RCA
|
|||
Chris Marrus
CCO
|
|||
Ivan Delevic
SVP Strategic Marketing and Business Development
|
|||
|
Jack Campo
Chief Legal Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Maurice Ferre, M.D. invest in?
Maurice Ferre, M.D. invests primarily in Medical Device, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Maurice Ferre, M.D.'s check size?
Maurice Ferre, M.D. typically joins rounds of $10M–$30M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Maurice Ferre, M.D. participates in.
How do I contact Maurice Ferre, M.D.?
Public channels for Maurice Ferre, M.D. include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Maurice Ferre, M.D. last invest?
The most recent investment recorded for Maurice Ferre, M.D. closed in Jun 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
